Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 17, 2022
October 17, 2022
f687702e-a09a-4529-b573-6d8a028c8779
Related Documents
Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products
Guidance DocumentAugust 10, 2023Office of the Commissioner
Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics
Guidance DocumentMarch 24, 2023Office of the Commissioner
Risk Management Plans to Mitigate the Potential for Drug Shortages
Guidance DocumentMay 19, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox